Publicacions en què col·labora amb Luis Paz-Ares Rodríguez (14)

2024

  1. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2018

  1. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

2017

  1. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

    Investigational New Drugs, Vol. 35, Núm. 2, pp. 198-206

2016

  1. IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)

    Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2183-2192

2014

  1. Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately after Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer

    Clinical Lung Cancer, Vol. 15, Núm. 6, pp. 418-425

  2. Treatment for early-stage lung cancer: What next?

    The Lancet

2013

  1. Identification of proteomic signatures associated with lung cancer and COPD

    Journal of Proteomics, Vol. 89, pp. 227-237

  2. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 23, pp. 2895-2902

2012

  1. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 247-255

  2. Review of treatment of patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor-activating EGFR mutations

    Cancer and Chemotherapy Reviews, Vol. 7, Núm. 2, pp. 59-64

  3. Safety, resource use, and quality of life in paramount: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

    Journal of Thoracic Oncology, Vol. 7, Núm. 11, pp. 1713-1721

2011

  1. Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 29, Núm. 7

  2. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

    Journal of Clinical Oncology, Vol. 29, Núm. 28, pp. 3783-3790

2009

  1. Medical emergencies

    Textbook of Medical Oncology: Fourth Edition (CRC Press), pp. 323-350